Graham Hood speaks with The Globe and Mail’s Robyn Doolittle on the Labubu craze and counterfeits
Recently, Principal Graham Hood spoke with The Globe and Mail’s Robyn Doolittle on counterfeit Labubus, a toy that has gained worldwide popularity. The toys have become so popular that counterfeits, commonly referred to as “Lafufus”, are being produced and sold worldwide.
Graham notes that brand owners are typically responsible for policing counterfeit goods, saying “occasionally law enforcement will get involved, but that tends to happen where there is some crossover with dealings in counterfeit goods and dealings with other illicit items, such as guns and drugs.”
Graham encourages companies to take steps to protect their intellectual property and trademark rights, since counterfeits can undermine consumers’ trust in their brands and undercut sales of their genuine products. He recommends that brand owners register their trademark rights and copyrights with the Canada Border Services Agency, which will keep an eye out for shipments of counterfeits and, with brand owners’ help, stop them from entering the country.
Read the full article on The Globe & Mail website (subscription required).
Related News & Media
-
Reshika Dhir examines Canadian IP retention in TheFutureEconomy.ca
Principal Reshika Dhir recently wrote a piece featured in TheFutureEconomy.ca exploring a growing challenge in Canada’s innovation economy: the quiet migration of valuable intellectual property to ot...Read More -
Principals Noel Courage and Ainslie Parsons explore strategies for protecting new plant varieties across key markets
Principals Ainslie Parsons and Noel Courage, along with expert international coauthors, recently contributed to an article in The Patent Lawyer Magazine examining how plant breeders and biotechs can p...Read More -
Janice Bereskin and Tamara Céline Winegust discuss a key trademark ruling in Canada for the Pharmaceutical Trade Marks Group
Principals Janice Bereskin and Tamara Céline Winegust recently wrote a feature for the March 2026 edition of Spotlight from the Pharmaceutical Trade Marks Group, exploring the implications of the rece...Read More
